CN110234349B - 特异性地结合人il-15的抗体及其用途 - Google Patents

特异性地结合人il-15的抗体及其用途 Download PDF

Info

Publication number
CN110234349B
CN110234349B CN201780079926.6A CN201780079926A CN110234349B CN 110234349 B CN110234349 B CN 110234349B CN 201780079926 A CN201780079926 A CN 201780079926A CN 110234349 B CN110234349 B CN 110234349B
Authority
CN
China
Prior art keywords
ser
seq
antibody
val
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780079926.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110234349A (zh
Inventor
大卫·约瑟·西蒙·莱恩
马修·波拉德
安东尼·杰拉德·道尔
林恩·多萝西·普尔顿
亚当·威廉·克拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Safran SA
Original Assignee
Safran SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Safran SA filed Critical Safran SA
Publication of CN110234349A publication Critical patent/CN110234349A/zh
Application granted granted Critical
Publication of CN110234349B publication Critical patent/CN110234349B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
CN201780079926.6A 2016-12-21 2017-12-21 特异性地结合人il-15的抗体及其用途 Active CN110234349B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
US62/437,143 2016-12-21
PCT/US2017/067917 WO2018119246A1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof

Publications (2)

Publication Number Publication Date
CN110234349A CN110234349A (zh) 2019-09-13
CN110234349B true CN110234349B (zh) 2024-03-22

Family

ID=62627610

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780079926.6A Active CN110234349B (zh) 2016-12-21 2017-12-21 特异性地结合人il-15的抗体及其用途

Country Status (30)

Country Link
US (2) US11267883B2 (https=)
EP (2) EP3558369B1 (https=)
JP (2) JP7155126B2 (https=)
KR (2) KR20190097094A (https=)
CN (1) CN110234349B (https=)
AR (1) AR110414A1 (https=)
AU (2) AU2017382850B2 (https=)
BR (1) BR112019012570A8 (https=)
CA (1) CA3046387A1 (https=)
CL (1) CL2019001729A1 (https=)
DK (1) DK3558369T3 (https=)
EA (1) EA201991514A1 (https=)
ES (1) ES3026508T3 (https=)
FI (1) FI3558369T3 (https=)
HR (1) HRP20250482T1 (https=)
HU (1) HUE071878T2 (https=)
IL (1) IL267113B2 (https=)
LT (1) LT3558369T (https=)
MA (1) MA47130B1 (https=)
MD (1) MD3558369T2 (https=)
MX (2) MX2019007357A (https=)
PE (1) PE20191497A1 (https=)
PH (1) PH12019501453A1 (https=)
PL (1) PL3558369T3 (https=)
PT (1) PT3558369T (https=)
RS (1) RS66900B1 (https=)
SI (1) SI3558369T1 (https=)
UA (1) UA126284C2 (https=)
WO (1) WO2018119246A1 (https=)
ZA (1) ZA201903848B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
US10417457B2 (en) 2016-09-21 2019-09-17 Twist Bioscience Corporation Nucleic acid based data storage
DK3558369T3 (da) 2016-12-21 2025-05-19 Cephalon Llc Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
EP4556433A3 (en) 2017-02-22 2025-08-06 Twist Bioscience Corporation Nucleic acid based data storage
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
US11407837B2 (en) 2017-09-11 2022-08-09 Twist Bioscience Corporation GPCR binding proteins and synthesis thereof
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
CA3100739A1 (en) 2018-05-18 2019-11-21 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
WO2020139871A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
JP2022522668A (ja) 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
CN113766930B (zh) 2019-02-26 2025-07-22 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
US11332738B2 (en) 2019-06-21 2022-05-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
JP2022548783A (ja) 2019-09-23 2022-11-21 ツイスト バイオサイエンス コーポレーション 単一ドメイン抗体のバリアント核酸ライブラリー
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
US20220267450A1 (en) * 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2022082201A1 (en) * 2020-10-16 2022-04-21 Genentech, Inc. Anti-cleaved icaspase substrate antibodies and methods of use
KR20230147617A (ko) 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
CN116655771A (zh) * 2021-05-28 2023-08-29 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
MA71681A (fr) 2022-08-04 2025-05-30 Novartis Pharma Ag Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (en) * 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516378A1 (en) * 2003-02-26 2004-09-10 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
WO2006017853A2 (en) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
CN1780856A (zh) * 2003-02-26 2006-05-31 根马布股份公司 白介素15(il－15)的特异性人抗体
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
WO2016001275A1 (en) * 2014-07-02 2016-01-07 Calypso Biotech Sa Antibodies to il-15

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7132510B2 (en) 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
RS51829B (sr) * 2001-08-23 2012-02-29 Genmab A/S. Ljudska antitela specifična za interleukin 15 (il-15)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US8048992B2 (en) * 2005-02-28 2011-11-01 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
DK3622815T3 (da) * 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
KR20120104542A (ko) * 2009-10-15 2012-09-21 아보트 러보러터리즈 Ｉｌ?１ 결합 단백질
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
RU2014109038A (ru) 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
HRP20210096T1 (hr) * 2015-03-31 2021-03-05 Medimmune Limited Novi oblik il33, mutirani oblici il33, protutijela, testovi i postupci njegove upotrebe
AU2016411388A1 (en) * 2016-06-15 2018-11-08 Amgen Inc. Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
DK3558369T3 (da) 2016-12-21 2025-05-19 Cephalon Llc Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
CA2516378A1 (en) * 2003-02-26 2004-09-10 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
CN1780856A (zh) * 2003-02-26 2006-05-31 根马布股份公司 白介素15(il－15)的特异性人抗体
WO2006017853A2 (en) * 2004-08-11 2006-02-16 Beth Israel Deaconess Medical Center, Inc. Mutant interleukin-15-containing compositions and suppression of an immune response
CN101213297A (zh) * 2005-05-09 2008-07-02 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
WO2016001275A1 (en) * 2014-07-02 2016-01-07 Calypso Biotech Sa Antibodies to il-15

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Idntification of an interleukin-15alpha receptor binding site on human interleukin-15;Bernard J;《J. BIOL.CHEM》;20040604;第279卷(第23期);第24313-24322页 *
Targeting interleukin-15 in patients with rheumatoid arthritis-A-proof-of-concept study;Baslund BO;《ARTHRITIS & RHEUMATISM》;20050930;第52卷(第9期);第927-944页 *

Also Published As

Publication number Publication date
JP2022176324A (ja) 2022-11-25
US12410247B2 (en) 2025-09-09
PT3558369T (pt) 2025-05-06
EP3558369A4 (en) 2020-09-09
LT3558369T (lt) 2025-07-25
PE20191497A1 (es) 2019-10-21
SI3558369T1 (sl) 2025-06-30
IL267113B2 (en) 2024-09-01
MX2023014081A (es) 2023-12-06
ZA201903848B (en) 2023-02-22
HUE071878T2 (hu) 2025-09-28
US20200270339A1 (en) 2020-08-27
EP4585261A3 (en) 2025-08-13
UA126284C2 (uk) 2022-09-14
MX2019007357A (es) 2019-09-05
AU2025201185A1 (en) 2025-03-13
CN110234349A (zh) 2019-09-13
AU2017382850B2 (en) 2024-11-21
HRP20250482T1 (hr) 2025-06-20
PL3558369T3 (pl) 2025-06-23
EA201991514A1 (ru) 2019-12-30
FI3558369T3 (fi) 2025-05-02
AR110414A1 (es) 2019-03-27
EP4585261A2 (en) 2025-07-16
IL267113A (en) 2019-08-29
BR112019012570A8 (pt) 2023-01-24
MA47130A (fr) 2019-10-30
WO2018119246A1 (en) 2018-06-28
JP2020501583A (ja) 2020-01-23
IL267113B1 (en) 2024-05-01
EP3558369B1 (en) 2025-03-26
DK3558369T3 (da) 2025-05-19
KR102706743B1 (ko) 2024-09-19
EP3558369A1 (en) 2019-10-30
RS66900B1 (sr) 2025-07-31
JP7155126B2 (ja) 2022-10-18
ES3026508T3 (en) 2025-06-11
US20220127352A1 (en) 2022-04-28
KR20230135691A (ko) 2023-09-25
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
KR20190097094A (ko) 2019-08-20
US11267883B2 (en) 2022-03-08
MA47130B1 (fr) 2025-05-30
PH12019501453A1 (en) 2020-06-15
CA3046387A1 (en) 2018-06-28
MD3558369T2 (ro) 2025-08-31
BR112019012570A2 (pt) 2019-11-26

Similar Documents

Publication Publication Date Title
CN110234349B (zh) 特异性地结合人il-15的抗体及其用途
JP7610541B2 (ja) 結合タンパク質及びその使用方法
CN112135626B (zh) 抗tigit抗体及其用途
JP2022513694A (ja) 抗ｐｄ－ｌ１／抗４－１ｂｂ二重特異性抗体およびその使用
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN101454345A (zh) 人il-6受体的高亲和力抗体
TW201722990A (zh) 特異性結合tl1a之抗體
TW202128770A (zh) 新型多肽複合物
TW202136303A (zh) 抗mertk抗體及其使用方法
JP2021513328A (ja) 抗ｍｓ４ａ６ａ抗体及びその使用方法
TW202221039A (zh) 犬及貓抑瘤素Ｍ受體β之抗體及其用途
CA3065553A1 (en) Il17a antibodies and antagonists for veterinary use
CN111448214B (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
CN120693345A (zh) 抗il18结合蛋白抗体及其使用方法
HK40129159A (en) Antibodies that specifically bind to human il-15 and uses thereof
BR122024020794A2 (pt) Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
HK40013673B (en) Antibodies that specifically bind to human il-15 and uses thereof
HK40013673A (en) Antibodies that specifically bind to human il-15 and uses thereof
EA040821B1 (ru) Антитела, которые специфически связываются с ил-15, и их применение
TW202532437A (zh) Cfc1結合分子
HK40042152A (en) Anti-tigit antibody and uses thereof
HK40042152B (zh) 抗tigit抗体及其用途
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Westchester, Pennsylvania, USA

Applicant after: CEPHALON, Inc.

Address before: Pennsylvania, America

Applicant before: CEPHALON, Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Westchester, Pennsylvania, USA

Applicant after: Safran Co.,Ltd.

Address before: Westchester, Pennsylvania, USA

Applicant before: CEPHALON, Inc.

GR01 Patent grant
GR01 Patent grant